Navigation Links
Real Time Genomics Announces Formation of its Scientific Advisory Board

San Francisco, CA (PRWEB) March 07, 2013

Real Time Genomics, Inc., the genome analytics company, today announced the formation of its Scientific Advisory Board (SAB) to provide guidance and expertise as the company develops tools to improve the accuracy and utility of genomic sequencing in the research of human disease.

Founding members of the SAB include Dr. George Weinstock, Associate Director of The Genome Institute at Washington University School of Medicine, Dr. Timothy Triche, Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles and the Associate Director of the Pediatric Institute of Molecular Medicine at Phoenix Children’s Hospital, and Dr. Gene Myers, Director of the Center for Systems Biology at the Max Planck Institute, Dresden.

“We are very pleased to welcome three scientists as talented as George, Tim and Gene to our SAB,” said Steve Lombardi, Chief Executive Officer of Real Time Genomics. “Their track records of success in their respective fields are exemplary and reflect their status as world-class genomics scientists. Their addition to the leadership of RTG greatly expands our knowledge of the progress and direction of the technology, science and medical vectors that influence the adoption of genomics to both life science research and personalized medicine.”

“Real Time Genomics has assembled a exceptional team of scientific, engineering, and business leaders all focused on delivering the most accurate and cost effective results for medical and biological application,” said Dr. Weinstock, who will Chair the Scientific Advisory Board. “Their platform has proven to be accurate, reliable and robust. I am pleased to join RTG’s scientific advisory board and look forward to guiding the company as it pursues its important mission.”

Dr. Weinstock applies high-throughput DNA sequencing, genome-wide analysis, bioinformatics, and other genetic methods in his role as Associate Director of the Genome Institute at Washington University. He is recognized worldwide as a leader of the Human Microbiome Project, studying the genomes of both host and microbiome organisms to characterize the communities they form and measure how communities change in different health and disease states. Previously, Dr. Weinstock was professor in the department of molecular and human genetics, the department of molecular virology and microbiology, and co-director of the Human Genome Sequencing Center of the Baylor College of Medicine. He was one of the leaders of the Human Genome Project and also of the first personal genome project, sequencing Dr. James Watson’s genome using next-generation sequencing technology. He received his B.S. degree from the University of Michigan in 1970 and his Ph.D. from the Massachusetts Institute of Technology in 1977.

Dr. Triche's research focuses on the genetic aspects of cancer biology. Combined with his record of success in leadership positions at CHLA and USC, he was appointed to the Directorship positions at CHLA and Phoenix Children's Hospital. He is also associated with the Children’s Oncology Group (COG), where he is presently a member of the executive committee, the scientific council and associate chair for translational research. Previously, he was chair of the Department of Pathology & Laboratory Medicine and pathologist-in-chief at Childrens Hospital Los Angeles, and a professor in the Department of Pathology & Laboratory Medicine and vice chairman of the Department of Pathology at the Keck School of Medicine at the University of Southern California. Prior to CHLA/USC, he served as the Chief of the Ultrastructural Laboratory of the Division of Pathology at the National Cancer Institute. He also serves as the Chief Medical Officer at NanoValent Pharmaceuticals, Inc., and previously was the Chairman and Chief Executive Officer of Oncormed, Inc. Dr. Triche received an A.B. from Cornell University in 1966, and in 1971 received both a Ph.D. in cell biology and an M.D. from Tulane University.

Dr. Myers is a pioneer in bioinformatics. Among his many accomplishments, he is best known as the creator of BLAST and the whole-genome shotgun protocol and assembler — which he applied while at Celera Genomics to assemble the human genome. More recently his research has focused on analyzing and extracting information from images obtained by various forms of microscopy. Previously, Dr. Myers was Group Leader, HHMI Janelia Farm Research Campus, Professor of Computer Science & MCB, UC Berkeley, and Vice President of Informatics Research, Celera Genomics. He received his Ph.D. in Computer Science from the University of Colorado, Boulder, and then moved to University of Arizona, Tucson, where he was Professor of Computer Science and Molecular and Cellular Biology before joining Craig Venter at Celera to tackle the largest shot-gun assembly project: the human genome.

About Real Time Genomics, Inc.
Real Time Genomics ( has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomic data. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

Steve Lombardi
President & CEO

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Real Time Genomics® Announces Platform Launch, Expanding Commercial Operations
2. TopCoders Open Community Challenge Process Yields 970 Fold Increase in Speed for Big Data Genomics Sequencing Algorithm
3. Boston Childrens Hospital announces international genomics competition winner
4. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
5. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
6. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics:
7. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
8. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
9. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
10. First Plant Genomics Yield Technology Progresses
11. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
Post Your Comments:
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):